MSD
Lynparza extends progression-free survival in gBRCAm metastatic pancreatic cancer
February 26, 2019Manufacturing and Production, Sales and Marketing AstraZeneca, Cancer, MSD, Pancreatic cancer, lynparza, pharma
AstraZeneca and MSD have lifted the curtain on new Phase 3 data for Lynparza (olaparib), confirming that the drug generated …
Keytruda falls short at Phase 3 in advanced liver cancer
February 20, 2019Research and Development Cancer, MSD, keytruda, liver cancer, pharma
MSD has revealed new Phase 3 data which indicates that its blockbuster immunotherapy Keytruda (pembrolizumab), in combination with best supportive …
MSD’s Keytruda combo therapy significantly improves survival in advanced renal cell carcinoma
February 18, 2019Sales and Marketing Cancer, MSD, Merck Sutent, Pfizer, inlyta, keytruda, oncology, rcc, renal cell carcinoma
Merck & Co’s Keytruda (pembrolizumab) in combination with Pfizer’s Inlyta (axitinib) significantly extended the lives of those with advanced renal …
Keytruda + Inlyta combo beats Pfizer’s chemotherapy Sutent in renal cell carcinoma
February 12, 2019Manufacturing and Production, Research and Development Cancer, MSD, Pfizer, inlyta, keytruda, pharma, renal cell carcinoma
New data has been revealed on the efficacy of MSD’s Keytruda (pembrolizumab) in combination with Pfizer’s Inlyta (axitinib), showing it …
MSD’s Keytruda boosts overall survival by 31% in advanced oesophageal cancer
January 16, 2019Research and Development Cancer, MSD, keytruda, oesophageal cancer, pharma
MSD has unveiled new Phase 3 data for its blockbuster anti-PD-1 immunotherapy Keytruda (pembrolizumab), showing that the drug succeeded in …
MSD chalks up two HIV drug approvals in Europe
November 30, 2018Medical Communications, Sales and Marketing Delstrigo, EU, Europe, HIV, MSD, Pifeltro, pharma
MSD has announced the European approval of two of its products for the treatment of HIV: the single-tablet combination Delstrigo …
MSD’s Keytruda to treat melanoma in England on the Cancer Drugs Fund
November 19, 2018Sales and Marketing England, MSD, NHS, UK, keytruda, melanoma, pharma
MSD’s blockbuster immunotherapy Keytruda (pembrolizumab) will now be made available to patients in England via the Cancer Drugs Fund, it …
MSD’s Keytruda improvess overall survival in Phase 3 oesophageal cancer
November 15, 2018Research and Development Cancer, MSD, PD-L1, keytruda, pharma
MSD has announced new Phase 3 data on its anti-PD-1 therapy Keytruda (pembrolizumab) as a second-line treatment for advanced or …
MSD’s Keytruda/chemo combo scores first-line FDA approval in NSC lung cancer
November 1, 2018Sales and Marketing Cancer, MSD, NSCLC, keytruda, lung cancer, pharma
MSD’s blockbuster anti-PD-1 immunotherapy has secured another FDA approval, it has emerged, in combination with carboplatin and either paclitaxel or …
First-line Keytruda shows better overall survival in head & neck cancer
October 23, 2018Manufacturing and Production, Research and Development Cancer, ESMO 2018, MSD, head and neck cancer, keytruda, pharma
MSD’s Keytruda (pembrolizumab) made an impact at the European Society for Medical Oncology 2018 Congress as the company unveiled new …
MSD’s Keytruda with Pfizer’s Inlyta beats Sutent in most common kidney cancer
October 19, 2018Medical Communications, Research and Development Cancer, Kidney cancer, MSD, Pfizer, inlyta, keytruda, pharma
MSD has unveiled new Phase 3 data on its blockbuster anti-PD-1 cancer therapy Keytruda (pembrolizumab) as part of a combination, …
MSD and Samsung Bioepis terminate development of Lantus biosimilar for diabetes
October 15, 2018Research and Development, Sales and Marketing Lantus, MSD, Samsung Bioepis, Sanofi, biosimilar, diabetes, pharma
MSD has reportedly terminated a previous agreement with Samsung Bioepis which would have seen them collaborate on a biosimilar version …
MSD signs $117m deal with Samsung Bioepis over Janssen biosimilar
October 8, 2018Sales and Marketing Biogen, Janssen, MSD, Samsung, Samsung Bioepis
American multinational MSD have won a $117 million contract allowing them to supply Samsung Bioepis’ Renflexis to the US Department …
Memorial Sloan Kettering Chief resigns from MSD board
October 3, 2018Research and Development MSD, Memorial Sloan Kettering Cancer Center, pharma
Dr Craig Thompson, Chief Executive of Memorial Sloan Kettering Cancer Center (MSKCC), the renowned non-profit treatment and research institution based …
Kenneth Frazier to continue as CEO as MSD rescinds mandatory retirement policy
September 27, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Kenneth Frazier, MSD, pharma
MSD has pitched a curveball with the news that the company has rescinded its policy mandating that Chief Executive Officers …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
